Clinical Trial of Pulmonary Cryptococcosis in China

Zhixin Liang260 enrolled

Overview

The purpose of the study:1.Improve the understanding of the risk factors of pulmonary cryptococcosis;2.Improve the awareness of pulmonary cryptococcosis clinical and imaging manifestations;3.Grasp pulmonary cryptococcosis patients of clinical and imaging manifestations in different conditions;4.Learn about antibacterial activity of antifungal drugs for cryptococcosis in China.

1. Patients corresponding to inclusion criteria and obtaining informed consent are included in the research in department of respiration ward in cooperative hospitals. 2. Relevant case report forms are created in this study. 3. Basic information such as age,weight and height is recorded in selected cases.Clinical manifestations,risk factors,laboratory examination,imaging examination,etiological examination and histopathological examination are also recorded in selected cases by case report forms.In addition,antifungal treatment is recorded including name,dose,time of starting treatment and terminate treatment.Causes of terminate treatment and curative effect evaluation should be analysed. 4. Statistical analysis.

Study Type

OBSERVATIONAL

Enrollment

260

Conditions

Cryptococcosis

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: Patients possess clinical or imaging manifestations of pulmonary infections,with any of the results(by one of following conditions) by microbiological examination or histopathologic examination 1. Cryptococcal capsular polysaccharide antigen of blood or pleural effusion is positive 2. Cryptococcus（fungus culture) is discovered by lower respiratory tract specimens 3. Cryptococcus（pleural effusions culture) is discovered by pleural effusions collected under sterile condition 4. Cryptococcus（pus culture) is discovered by pus smear out of pulmonary infections in disseminated infection patients 5. Cryptococcus（blood culture) is discovered by microscopy of specimens of blood smear 6. Cryptococcus is discovered by culturing of the pathological tissue specimens in aseptic condition 7. Cryptococcal capsular budding yeast with inflammatory reaction is discovered by histopathological examination,cell pathology examination or microscopic examination in aseptic condition Exclusion Criteria: 1. Patients suffer from acquired immune deficiency syndrome 2. Patients or their legal guardians request to withdraw the clinical research

Outcomes

Primary Outcomes

differences in clinical manifestations of pulmonary cryptococcosis

Methods including laboratory examination(routine blood test),imaging examination(chest CT),scoring system(APACHE II score)

Time frame: 30 days

Secondary Outcomes

treatment of pulmonary cryptococcosis

Efficacy as measured by recording dose and time of therapy for antifungal agents

Time frame: 30 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.